Perlmutter Cancer Center at NYU Langone Health· @Perlmutter_CC · X·· 22 hours agoScore45
Body
Today at #ESMO2026, PCC’s Kristen Spencer, DO, (@kspencer725) presents research on novel targeted therapies for colorectal cancer, including KRAS G12D inhibitors and treatment approaches for MCC CRC.
@myESMO @nyugrossman
4 views · 0 likes · 0 reposts · 0 replies
Conference abstracts
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683Pmatched by NSCLC, metastatic
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.orgSource: Perlmutter Cancer Center at NYU Langone Health · x.com